MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Time CEO Austin Vanchieri Becomes Executive Chair NORTH CANTON, OHIO / ACCESS Newswire / July 1, 2025 / Visual Edge IT, Inc., ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying. Aims: To assess ...

Objectives To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight. Design Meta-analysis of available data from randomised controlled ...

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

The chemokine receptor CXCR7 is an atypical CXCL12 receptor that, as opposed to the classical CXCL12 receptor CXCR4, signals preferentially via the β-arrestin pathway and does not mediate chemotaxis.